The aim of the present trial is therefore twofold: (1) to clarify whether 12 weekly EPO versus placebo (saline) treatment has pro-cognitive effects in cognitively impaired remitted patients with BD or recurrent UD and first-degree relatives without mood or psychotic disorders to patients with BD, recurrent UD, or schizophrenia; and (2) to identify patterns of early treatment-related neural activity change that may be predictive of subsequent cognitive improvement. The gene discussed is EPO; the disease is Behcet disease.